期刊
CRITICAL REVIEWS IN BIOTECHNOLOGY
卷 42, 期 7, 页码 1079-1098出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/07388551.2021.1988509
关键词
Cancer immunotherapy; chimeric antigen receptor; tumor microenvironment; infiltration; solid tumors; tumor vasculature; stroma; tumor islets
资金
- National Institute for Medical Research Development (NIMAD) [984179]
CAR-T therapy has shown success in treating blood-based malignancies, but faces challenges in treating solid tumors due to the hostile tumor microenvironment hindering effective infiltration and function of CAR-T cells.
Chimeric antigen receptor T cell (CAR-T) therapy has been recognized as one of the most prosperous treatment options against certain blood-based malignancies. However, the same clinical and commercial success have been out of range in the case of solid tumors. The main contributing factor in this regard is the hostile environment the tumor cells impose that results in the exhaustion of immune effector cells alongside the abrogation of their infiltration capacity. The discovery of the underlying mechanisms and the development of reliable counterstrategies to overcome the inaccessibility of CAR-Ts to their target cells might correlate with encouraging clinical outcomes in advanced solid tumors. Here, we highlight the successive physical and metabolic barriers that systemically administered CAR-Ts face on their journey toward their target cells. Moreover, we propose meticulously-devised countertactics and combination therapies that can be applied to maximize the therapeutic benefits of CAR-T therapies against solid tumors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据